2014
Treatment of Hodgkin Lymphoma: A 50-Year Perspective
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, DeVita VT. Treatment of Hodgkin Lymphoma: A 50-Year Perspective. Journal Of Clinical Oncology 2014, 32: 163-168. PMID: 24441526, DOI: 10.1200/jco.2013.53.1194.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBleomycinClinical Trials as TopicCyclophosphamideDacarbazineDisease-Free SurvivalDoxorubicinEtoposideEuropeHistory, 20th CenturyHodgkin DiseaseHumansMechlorethamineNeoplasm StagingPositron-Emission TomographyPrednisoneProcarbazineSurvival RateTomography, X-Ray ComputedTreatment OutcomeVinblastineVincristine
2009
Off-label use of approved drugs
DeVita V. Off-label use of approved drugs. Nature Reviews Clinical Oncology 2009, 6: 181-181. PMID: 19333219, DOI: 10.1038/nrclinonc.2009.41.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicColonic NeoplasmsDrug ApprovalDrug LabelingEflornithineGovernment RegulationHumansSulindacUnited StatesUnited States Food and Drug Administration
2008
The era of personalized medicine: back to basics
Hutchinson L, DeVita V. The era of personalized medicine: back to basics. Nature Reviews Clinical Oncology 2008, 5: 623-623. PMID: 18957968, DOI: 10.1038/ncponc1253.Peer-Reviewed Original ResearchAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBiomarkers, TumorCarcinoma, Non-Small-Cell LungCetuximabClinical Trials as TopicColorectal NeoplasmsDrug Delivery SystemsDrug Resistance, NeoplasmGene TargetingGenes, erbB-1HumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLung NeoplasmsPanitumumabPatient-Centered CarePiperazinesPyrimidinesTreatment Outcome
2005
Shifting paradigms in lung cancer
DeVita V. Shifting paradigms in lung cancer. Nature Reviews Clinical Oncology 2005, 2: 535-535. PMID: 16270076, DOI: 10.1038/ncponc0345.Peer-Reviewed Original ResearchThe curse of the cure
DeVita V. The curse of the cure. Nature Reviews Clinical Oncology 2005, 2: 1-1. PMID: 16264829, DOI: 10.1038/ncponc0054.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsChildChild WelfareClinical Trials as TopicHodgkin DiseaseHumansLeukemiaMedical OncologyPatient SelectionQuality of LifeTreatment Outcome
1997
Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo D, Glatstein E, Duffey P, Young R, Ihde D, Bastian A, Wilson W, Wittes R, Jaffe E, Hubbard S, DeVita V. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. Journal Of Clinical Oncology 1997, 15: 3338-46. PMID: 9363863, DOI: 10.1200/jco.1997.15.11.3338.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedPrednisoneProcarbazineProspective StudiesTreatment OutcomeVinblastineVincristineConceptsMantle field radiation therapyDisease-free survivalLarge mediastinal massMediastinal Hodgkin's diseaseHodgkin's diseaseABVD chemotherapyRadiation therapyOverall survivalMediastinal massMOPP/ABVDSecond solid tumorsTreatment-related pneumonitisComplete response rateAnn Arbor stageClinical prognostic factorsErythrocyte sedimentation rateTreatment of patientsAge 35 yearsLactate dehydrogenase levelsABVD therapyDacarbazine (ABVD) chemotherapyMedian followMOPP chemotherapySalvage therapyB symptoms
1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1993
Dose Intensity
SURBONE A, DeVITA V. Dose Intensity. Annals Of The New York Academy Of Sciences 1993, 698: 279-288. PMID: 8279768, DOI: 10.1111/j.1749-6632.1993.tb17219.x.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials as TopicCyclophosphamideDose-Response Relationship, DrugFemaleFluorouracilHumansMethotrexateMulticenter Studies as TopicResearch DesignTreatment OutcomeCHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma
Longo D, DeVita V, Young R. CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma. New England Journal Of Medicine 1993, 329: 580-582. PMID: 7687747, DOI: 10.1056/nejm199308193290817.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsBleomycinCyclophosphamideCytarabineDoxorubicinEtoposideHumansLymphoma, Non-HodgkinMethotrexatePrednisoneVincristineIs alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? No.
DeVita V. Is alternating cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? No. Important Advances In Oncology 1993, 197-208. PMID: 8505053.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleHodgkin DiseaseHumans
1992
Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast.
Longo D, Duffey P, Hubbard S, Young R, DeVita V. Radiation therapy is better than chemotherapy in early-stage Hodgkin's disease? Not so fast. Journal Of Clinical Oncology 1992, 10: 1367-9. PMID: 1634930, DOI: 10.1200/jco.1992.10.8.1367.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsHodgkin DiseaseHumansMechlorethaminePrednisoneProcarbazineTreatment OutcomeVincristineConventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsChildFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMiddle AgedProbabilityRecurrenceRemission InductionSalvage TherapySurvival AnalysisTreatment OutcomeConceptsComplete response rateInitial remissionComplete remissionCombination chemotherapyHodgkin's diseaseSalvage therapyOverall survivalPeripheral blood stem cell supportResponse rateChemotherapy-induced complete remissionConventional-dose salvage therapyDate of relapseDurable second remissionsRemission 5 yearsSalvage combination chemotherapyShort initial remissionTreatment-related complicationsDisease-free survivalClinical prognostic factorsStem cell supportDuration of responsePrimary treatment regimenRelapse of patientsNational Cancer InstituteB symptomsThe use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
Longo D, DeVita V. The use of combination chemotherapy in the treatment of early stage Hodgkin's disease. Important Advances In Oncology 1992, 155-65. PMID: 1582671.Peer-Reviewed Original Research
1991
The calculation of actual or received dose intensity: a comparison of published methods.
Longo D, Duffey P, DeVita V, Wesley M, Hubbard S, Young R. The calculation of actual or received dose intensity: a comparison of published methods. Journal Of Clinical Oncology 1991, 9: 2042-51. PMID: 1941063, DOI: 10.1200/jco.1991.9.11.2042.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesHumansLymphoma, Non-HodgkinMathematicsMiddle AgedPublishingConceptsSouthwest Oncology GroupTreatment courseEntire treatment coursePatient's treatment coursePrognostic factorsTreatment outcomesAggressive histology lymphomaCombination chemotherapy programsClinical prognostic factorsNational Cancer Institute studyDistinct patient populationsDose-related variablesDose intensityOncology GroupChemotherapy programPrognostic significancePatient populationStudy populationInstitute studyOutcomesRecent reportsEntire populationPopulationCourseDI dataTreatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDiseaseTreatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsChildCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRecurrenceRemission InductionSurvival RateVincristineConceptsMediastinal Hodgkin's diseaseDisease-free survivalComplete respondersModality treatmentHodgkin's diseaseNational Cancer InstituteComplete remissionRadiation therapyMantle radiation therapyStage IIB diseaseOverall survival differenceMOPP chemotherapyDurable remissionsIIB diseaseLate complicationsModality therapyOverall survivalComplete responseMediastinal massSubsequent therapyTumor mortalitySurvival differencesChest radiographsRetrospective analysisMaximal responseThe influence of information on drug resistance on protocol design The Henry Kaplan Memorial Lecture, International Conference on Mulignant Lymphomas, 6–9 June 1990, Lugano, Switzerland
DeVita V. The influence of information on drug resistance on protocol design The Henry Kaplan Memorial Lecture, International Conference on Mulignant Lymphomas, 6–9 June 1990, Lugano, Switzerland. Annals Of Oncology 1991, 2: 93-106. PMID: 2054322, DOI: 10.1093/oxfordjournals.annonc.a057892.Peer-Reviewed Original ResearchAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsClinical Trials as TopicDrug Administration ScheduleDrug ResistanceHumansNeoplasmsResearch DesignLong-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas
Fisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBleomycinCyclophosphamideCytarabineDoxorubicinDrug EvaluationEtoposideFollow-Up StudiesHumansLymphoma, Non-HodgkinMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineRemission InductionSurvival RateVincristineConceptsDisease-free survivalProMACE-MOPPCR rateComplete remissionProMACE-CytaBOMHodgkin's lymphomaLong-term disease-free survivalLong-term disease-free survivorsSurvival curvesStage IIDisease-free survival curvesFirst-generation regimensThird-generation regimensPhase II studyDisease-free survivorsOverall survival curvesSouthwest Oncology GroupCooperative group settingHigh-grade NHLNational Cancer InstituteSame time pointsVs 53Aggressive NHLII studyOncology GroupSuperiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsBleomycinCyclophosphamideCytarabineDoxorubicinEtoposideFemaleHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedNeoplasm StagingPrednisoneProcarbazineProspective StudiesRemission InductionSurvival RateVincristineConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaComplete response rateCo-trimoxazole prophylaxisDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rate
1989
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy.
Longo D, Glatstein E, Duffey P, Ihde D, Hubbard S, Fisher R, Jaffe E, Gilliom M, Young R, DeVita V. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. Journal Of Clinical Oncology 1989, 7: 1295-302. PMID: 2788716, DOI: 10.1200/jco.1989.7.9.1295.Peer-Reviewed Original ResearchConceptsInvolved field radiation therapyRadiation therapyComplete remissionAggressive lymphomaCoronary artery bypass surgeryInvolved-field radiation therapyEarly hematogenous disseminationLocalized aggressive lymphomaTreatment-related deathsClinical stage IHigh-dose methotrexateArtery bypass surgeryCombination chemotherapy programsCycles of treatmentMedian followAggressive histologyBypass surgeryLeucovorin rescueChemotherapy programCombination chemotherapyHospital admissionLocal therapyHematogenous disseminationEffective treatmentLymphoma histology